Sensitivity Study of Diagnostic for Early Detection of Dengue Infection
Launched by INBIOS INTERNATIONAL, INC. · Feb 10, 2014
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All age groups and both sexes.
- • Initial serum samples must be collected within 1- 7 days of onset of symptoms consistent with Dengue virus infection.
- • Information must be available about symptoms, age, and sex of patient from which samples are collected.
- • The location of sample collection must be recorded.
- • Archived samples that have been sent to reference labs for dengue or flavivirus testing should be considered for inclusion as test specimens in this study. If these specimens are included in this study, then they must have a documented history that the specimen was obtained within the first 7 days of onset of subject symptoms consistent with dengue infection.
- Exclusion Criteria:
- • Archived samples with linked personal identifiers or any sample for which personal information can be discovered.
- • Prospective samples from nursing home residents; inmates/subjects in police custody; participants who are unable to understand verbal or written local language in which a certified translation of the informed consent is available, or requires a Legal Authorized Representative (LAR) for consent.
- • Subject serum specimens that have undergone more than 2 freeze-thaw cycles or that have not been stored frozen.
About Inbios International, Inc.
Inbios International, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative diagnostic solutions and therapeutics. With a strong focus on infectious diseases, Inbios leverages advanced technology and rigorous scientific research to create products that enhance disease detection and management. The company is committed to improving global health outcomes through its clinical trials and partnerships, ensuring that its solutions are safe, effective, and accessible to diverse populations. By prioritizing quality and compliance, Inbios International aims to be a leader in the diagnostic and therapeutic sectors, contributing to the advancement of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Medellin, , Colombia
Posadas, , Argentina
Bridgetown, , Barbados
Galle, , Sri Lanka
Bangkok, , Thailand
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials